Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead Pharmaceuticals Shares Are On The Rise Today: What's Going On?
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.Arrowhead Pharmaceuticals Inc. (NASDAQ:ARWR) shares are trading higher Tuesday after the company announced a global licensing and collaboration agreement with Sarepta Therapeutics Inc. (NASDAQ:SRPT). Here's what you need to know.
Arrowhead Pharmicals Inc.（納斯達克股票代碼：ARWR）週二股價走高，此前該公司宣佈與Sarepta Therapeutics Inc.（納斯達克股票代碼：SRPT）簽訂全球許可與合作協議。以下是你需要知道的。
What To Know: The partnership grants Sarepta exclusive worldwide rights to Arrowhead's investigational RNA interference (RNAi) therapies for rare genetic diseases targeting muscle, the central nervous system (CNS) and the lungs.
須知：該合作伙伴關係授予Sarepta全球獨家使用Arrowhead針對肌肉、中樞神經系統（CNS）和肺部的罕見遺傳性疾病的研究性RNA干擾（RNAi）療法。
The agreement focuses on Arrowhead's Targeted RNAi Molecule platform, which enables precise delivery of therapies designed to reduce the activity of disease-causing genes.
該協議側重於Arrowhead的靶向RNAi分子平台，該平台可以精確提供旨在降低致病基因活性的療法。
Arrowhead will receive an upfront payment of $500 million, as well as a $325 million equity investment from Sarepta at a 35% premium. Additional terms include $250 million to be paid in $50 million installments over five years, up to $300 million in near-term milestone payments over the next year and potential tiered royalties on commercial sales.
Arrowhead將獲得5億美元的預付款，以及來自Sarepta的3.25億美元股權投資，溢價爲35％。其他條款包括在五年內分期支付2.5億美元，在五年內分期支付高達3億美元的近期里程碑式付款，以及潛在的商業銷售分級特許權使用費。
Arrowhead CEO Christopher Anzalone called the agreement transformative, noting that the influx of capital extends the company's financial runway through 2028. This timeline positions Arrowhead to pursue the commercial launch of its first product, plozasiran, pending regulatory approval.
Arrowhead首席執行官克里斯托弗·安扎隆稱該協議具有變革性，並指出資本的湧入將公司的財務狀況延長至2028年。該時間表使Arrowhead有望在監管部門批准之前開始其首款產品plozasiran的商業上市。
Sarepta sees the collaboration as a strategic expansion of its portfolio, complementing its expertise in gene therapy and Duchenne muscular dystrophy. Sarepta CEO Doug Ingram highlighted the potential for these RNAi programs to have a significant market impact. As part of the agreement, Ingram will join Arrowhead's Board of Directors.
Sarepta將此次合作視爲其產品組合的戰略擴展，補充了其在基因療法和杜興氏肌營養不良症方面的專業知識。薩雷普塔首席執行官道格·英格拉姆強調了這些RNAi計劃對市場產生重大影響的潛力。作爲協議的一部分，英格拉姆將加入Arrowhead的董事會。
"The agreement affords multiple potential blockbuster opportunities, serves our strategic priorities for the remainder of the decade and beyond and diversifies our business model across one-time therapies and chronic treatments allowing for long-term growth and success," Ingram said.
英格拉姆說：「該協議提供了多個潛在的重磅機遇，滿足了我們在本十年剩餘時間及以後的戰略優先事項，並在一次性療法和慢性治療方面實現了我們的業務模式的多元化，從而實現了長期增長和成功。」
The collaboration is expected to close in early 2025, pending regulatory approval. Both companies have emphasized the agreement's significance in advancing treatments for rare genetic diseases, with additional details anticipated in their upcoming investor presentations.
該合作預計將於2025年初結束，尚待監管部門批准。兩家公司都強調了該協議在推進罕見遺傳病治療方面的重要性，預計將在即將發佈的投資者報告中提供更多細節。
ARWR Price Action: Arrowhead Pharmaceuticals shares were up 16.7% at $21.94 at the time of writing, according to Benzinga Pro.
ARWR價格走勢：根據Benzinga Pro的數據，在撰寫本文時，Arrowhead Pharmicals的股價上漲了16.7％，至21.94美元。
- Merger-Bound Berry Global Agrees To Divest Specialty Tapes Unit For ~$540M
- 合併後的Berry Global同意以約5.4億美元的價格剝離特種膠帶部門
Image Via Shutterstock.
圖片來自 Shutterstock。
